日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

登録内容を編集ファイル形式で保存
 
 
ダウンロード電子メール
  The endocannabinoid system as a target for novel anxiolytic drugs

Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017). The endocannabinoid system as a target for novel anxiolytic drugs. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 76, 56-66. doi:10.1016/j.neubiorev.2016.12.033.

Item is

基本情報

表示: 非表示:
アイテムのパーマリンク: https://hdl.handle.net/21.11116/0000-0001-9EA5-3 版のパーマリンク: https://hdl.handle.net/21.11116/0000-0001-9EAB-D
資料種別: 学術論文

ファイル

表示: ファイル

関連URL

表示:

作成者

表示:
非表示:
 作成者:
Patel, Sachin1, 著者
Hill, Mathew N.1, 著者
Cheer, Joseph F.1, 著者
Wotjak, Carsten T.2, 著者           
Holmes, Andrew1, 著者
所属:
1external, ou_persistent22              
2Dept. Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Max Planck Society, ou_2035294              

内容説明

表示:
非表示:
キーワード: ACID AMIDE HYDROLASE; POSTTRAUMATIC-STRESS-DISORDER; DORSOLATERAL PERIAQUEDUCTAL GRAY; CANNABINOID CB1 RECEPTOR; MONOACYLGLYCEROL LIPASE BLOCKADE; ELEVATED PLUS-MAZE; SUBSTRATE-SELECTIVE INHIBITION; POSITRON-EMISSION-TOMOGRAPHY; VANILLOID TYPE-1 CHANNELS; CENTRAL-NERVOUS-SYSTEMBehavioral Sciences; Neurosciences & Neurology; Stress; Fear; PTSD; COX-2; CB1 receptor; Cannabis; Dopamine; Glucocorticoid; Cortisol; Amygdala; Hippocampus; Prefrontal cortex;
 要旨: The endocannabinoid (eCB) system has attracted attention for its role in various behavioral and brain functions, and as a therapeutic target in neuropsychiatric disease states, including anxiety disorders and other conditions resulting from dysfunctional responses to stress. In this mini-review, we highlight components of the eCB system that offer potential 'druggable' targets for new anxiolytic medications, emphasizing some of the less well-discussed options. We discuss how selectively amplifying eCBs recruitment by interfering with eCB-degradation, via fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), has been linked to reductions in anxiety-like behaviors in rodents and variation in human anxiety symptoms. We also discuss a non-canonical route to regulate eCB degradation that involves interfering with cyclooxygenase-2 (COX-2). Next, we discuss approaches to targeting eCB receptor-signaling in ways that do not involve the cannabinoid receptor subtype 1 (CB1R); by targeting the CB2R subtype and the transient receptor potential vanilloid type 1 (TRPV1). Finally, we review evidence that cannabidiol (CBD), while representing a less specific pharmacological approach, may be another way to modulate eCBs and interacting neurotransmitter systems to alleviate anxiety. Taken together, these various approaches provide a range of plausible paths to developing novel compounds that could prove useful for treating trauma-related and anxiety disorders. Published by Elsevier Ltd.

資料詳細

表示:
非表示:
言語: eng - English
 日付: 2017
 出版の状態: 出版
 ページ: 11
 出版情報: -
 目次: -
 査読: -
 識別子(DOI, ISBNなど): ISI: 000400341700008
DOI: 10.1016/j.neubiorev.2016.12.033
 学位: -

関連イベント

表示:

訴訟

表示:

Project information

表示:

出版物 1

表示:
非表示:
出版物名: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
種別: 学術雑誌
 著者・編者:
所属:
出版社, 出版地: PERGAMON-ELSEVIER SCIENCE LTD
ページ: - 巻号: 76 通巻号: - 開始・終了ページ: 56 - 66 識別子(ISBN, ISSN, DOIなど): ISSN: 0149-7634